EGFR and lung adenocarcinoma: Osimertinib is the most recently approved third-generation EGFR-TKI, which can be effective in patients with advanced-stage lung adenocarcinoma harbouring an EGFR gene mutation and an acquired drug-resistant mutation, such as the exon 20 T790 M point mutation [20].